Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized, placebo-controlled first-in-human study of oral TQS-168 in healthy volunteers: Assessment of safety, tolerability, pharmacokinetics, pharmacodynamics, and food effect.
Hannestad J, Smith S, Lam A, Hurt J, Harada N, Kim R, Das A, Brunello J, Whitaker G, Chalmers D, Senjoti F, Lin W, Coghill J, Bansal Y, Sidhu S, Zann V, Liu E. Hannestad J, et al. Among authors: zann v. Clin Transl Sci. 2024 Nov;17(11):e70064. doi: 10.1111/cts.70064. Clin Transl Sci. 2024. PMID: 39535924 Free PMC article. Clinical Trial.
Discovery and Model-Informed Drug Development of a Controlled-Release Formulation of Nonracemic Amisulpride that Reduces Plasma Exposure but Achieves Pharmacodynamic Bioequivalence in the Brain.
Hopkins SC, Toongsuwan S, Corriveau TJ, Watanabe T, Tsushima Y, Asada T, Lew R, Shi L, Zann V, Snowden TJ, van der Graaf PH, Darpo B, Searle GE, Rabiner EA, Wilding I, Szabo ST, Galluppi GR, Koblan KS. Hopkins SC, et al. Among authors: zann v. Clin Pharmacol Ther. 2024 Aug;116(2):460-470. doi: 10.1002/cpt.3311. Epub 2024 May 31. Clin Pharmacol Ther. 2024. PMID: 38822554
Safety, Pharmacokinetics, and Pharmacodynamics of ME-401, an Oral, Potent, and Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, Following Single Ascending Dose Administration to Healthy Volunteers.
Moreno O, Butler T, Zann V, Willson A, Leung P, Connor A. Moreno O, et al. Among authors: zann v. Clin Ther. 2018 Nov;40(11):1855-1867. doi: 10.1016/j.clinthera.2018.09.006. Epub 2018 Oct 26. Clin Ther. 2018. PMID: 30458930 Free article. Clinical Trial.
Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacological Effect of Orally Administered CORT125134: An Adaptive, Double-Blind, Randomized, Placebo-Controlled Phase 1 Clinical Study.
Hunt H, Donaldson K, Strem M, Zann V, Leung P, Sweet S, Connor A, Combs D, Belanoff J. Hunt H, et al. Among authors: zann v. Clin Pharmacol Drug Dev. 2018 May;7(4):408-421. doi: 10.1002/cpdd.389. Epub 2017 Oct 2. Clin Pharmacol Drug Dev. 2018. PMID: 28967708 Free PMC article. Clinical Trial.
Novel formulation of abiraterone acetate might allow significant dose reduction and eliminates substantial positive food effect.
Solymosi T, Ötvös Z, Angi R, Ordasi B, Jordán T, Molnár L, McDermott J, Zann V, Church A, Mair S, Filipcsei G, Heltovics G, Glavinas H. Solymosi T, et al. Among authors: zann v. Cancer Chemother Pharmacol. 2017 Oct;80(4):723-728. doi: 10.1007/s00280-017-3406-6. Epub 2017 Aug 3. Cancer Chemother Pharmacol. 2017. PMID: 28776077 Clinical Trial.
14 results